Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 1-Year High – What’s Next?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) hit a new 52-week high during trading on Tuesday . The stock traded as high as $90.08 and last traded at $89.50, with a volume of 1229452 shares. The stock had previously closed at $86.57.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on MIRM shares. Raymond James Financial reissued a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Stifel Nicolaus increased their target price on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Cantor Fitzgerald restated an “overweight” rating and set a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Citizens Jmp lifted their price objective on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, December 19th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $100.25.

Mirum Pharmaceuticals Stock Up 3.4%

The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The stock has a 50-day simple moving average of $73.30 and a two-hundred day simple moving average of $68.25. The firm has a market cap of $4.60 billion, a PE ratio of -104.07 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.Mirum Pharmaceuticals’s quarterly revenue was up 47.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.30) EPS. Analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors have recently bought and sold shares of MIRM. SG Americas Securities LLC purchased a new position in Mirum Pharmaceuticals in the 4th quarter worth approximately $1,478,000. NorthCrest Asset Manangement LLC purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth $406,000. Tudor Investment Corp ET AL purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $2,027,000. CIBC Bancorp USA Inc. bought a new stake in Mirum Pharmaceuticals in the 3rd quarter worth $315,000. Finally, PharVision Advisers LLC bought a new stake in Mirum Pharmaceuticals in the 3rd quarter worth $273,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.